Angela Nelms - RenovoRx Chief Officer
| RNXT Stock | USD 0.99 0.02 2.06% |
Insider
Angela Nelms is Chief Officer of RenovoRx
| Age | 47 |
| Phone | 650 284 4433 |
| Web | https://renovorx.com |
Angela Nelms Latest Insider Activity
Tracking and analyzing the buying and selling activities of Angela Nelms against RenovoRx stock is an integral part of due diligence when investing in RenovoRx. Angela Nelms insider activity provides valuable insight into whether RenovoRx is net buyers or sellers over its current business cycle. Note, RenovoRx insiders must abide by specific rules, including filing SEC forms every time they buy or sell RenovoRx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Angela Nelms over a year ago Purchase by Angela Nelms of 300 shares of RenovoRx | ||
Angela Nelms over a year ago Acquisition by Angela Nelms of 32500 shares of RenovoRx subject to Rule 16b-3 |
RenovoRx Management Efficiency
The company has return on total asset (ROA) of (0.9331) % which means that it has lost $0.9331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5895) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| James CPA | Longeveron LLC | 58 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| MBA MD | Ikena Oncology | 59 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Eddie Sullivan | SAB Biotherapeutics | 59 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| KwanHong MD | Longeveron LLC | 57 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Mark Peikin | Adial Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Catherine Fratila | Adial Pharmaceuticals | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 55 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| MBA MD | Monopar Therapeutics | 38 | |
Management Performance
| Return On Equity | -2.59 | ||||
| Return On Asset | -0.93 |
RenovoRx Leadership Team
Elected by the shareholders, the RenovoRx's board of directors comprises two types of representatives: RenovoRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RenovoRx. The board's role is to monitor RenovoRx's management team and ensure that shareholders' interests are well served. RenovoRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RenovoRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald CPA, VP Controller | ||
| James Ahlers, Chief Officer | ||
| Leesa Gentry, Senior Operations | ||
| Angela Nelms, Chief Officer | ||
| Ryan Witt, Senior Partnerships | ||
| Robert Strasser, Vice RD | ||
| Ramtin MD, Chairman Founder | ||
| CGMA CPA, Controller VP | ||
| Shaun Bagai, Secretary CEO |
RenovoRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RenovoRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.59 | ||||
| Return On Asset | -0.93 | ||||
| Current Valuation | 25.08 M | ||||
| Shares Outstanding | 35.57 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 2.85 % | ||||
| Number Of Shares Shorted | 205.91 K | ||||
| Price To Book | 4.90 X | ||||
| EBITDA | (11.39 M) | ||||
| Net Income | (10.23 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.